Antimicrobial Susceptibility Testing Market is expected to be valued at USD 3,645.3 million in 2022, growing at a 6.2% CAGR from 2022 to 2028. Antimicrobial susceptibility testing (AST) is a laboratory procedure to identify an accurate antimicrobial regimen against microbes. AST of the connective agent(s) is essential for judiciously selecting appropriate antimicrobial therapy. The market is primarily driven by the increasing number of pathogenic bacteria gaining antibiotic resistance and new forms of resistance are steadily emerging, which enable clinicians to execute antimicrobial susceptibility testing (AST) with urgency. A rapid multiplexed AST platform delivers minimum inhibitory concentrations (MICs) within hours at a feasible cost, which empowers rapid determination of effective targeted bacteriophage therapy, ensuing in short hospital stays, and fewer laboratory tests, decreasing morbidity and mortality along with their healthcare expenses. These advancements in the health care sector further enhance the Antimicrobial Susceptibility Testing Market growth. Furthermore, the increasing number of new launches of products based on various technologies are expected to push the market growth. For instance, the CE-marked Alfred 60 AST system of Alifax S.r.l. Italy, a company specializing in the development, production, and distribution of automated clinical diagnostic instruments, practices sensitive laser-light scattering technology to detect bacterial growth in a liquid culture broth and provides antimicrobial susceptibility results directly from positive blood culture bottles within 4–6 hours. Furthermore, in 2018, Beckman Coulter Inc., a subsidiary of Danaher, announced the commercialization of its DxM MicroScan WalkAway system, a diagnostic solution for bacterial detection and antibiotic susceptibility testing for microbiology research laboratories.
Recent Market Developments:
In February 2020, Bio-Rad Laboratories, Inc., a global company engaged in developing, manufacturing, and marketing an extensive range of innovative products for the life science research and clinical diagnostic markets, developed Exact Diagnostics.